Pages that link to "Q28272279"
Jump to navigation
Jump to search
The following pages link to Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin (Q28272279):
Displaying 50 items.
- Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial (Q28236480) (← links)
- The role of CETP inhibition in dyslipidemia (Q28249333) (← links)
- JTT-705: is there still future for a CETP inhibitor after torcetrapib? (Q28294797) (← links)
- Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction (Q29999973) (← links)
- The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia. (Q30380628) (← links)
- Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors (Q33590777) (← links)
- Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics. (Q34441411) (← links)
- Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis (Q35034986) (← links)
- Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters (Q35380101) (← links)
- The inhibition of cholesteryl ester transfer protein: a long and winding road (Q35958413) (← links)
- Cholesterol efflux capacity, macrophage reverse cholesterol transport and cardioprotective HDL. (Q36197563) (← links)
- Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib (Q36197709) (← links)
- High-Density Lipoprotein - A Hero, a Mirage, or a Witness? (Q36344712) (← links)
- Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence (Q36422727) (← links)
- Will torcetrapib be the next big thing in coronary heart disease risk reduction? (Q36684192) (← links)
- CETP inhibition in cardiovascular risk management: a critical appraisal (Q36705260) (← links)
- Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone (Q36736504) (← links)
- High-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome (Q36975872) (← links)
- Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease (Q36992708) (← links)
- Residual risk in statin-treated patients: future therapeutic options (Q37000088) (← links)
- Effect of obesity on high-density lipoprotein metabolism (Q37058273) (← links)
- Is raising HDL a futile strategy for atheroprotection? (Q37073546) (← links)
- In vivo effects of anacetrapib on preβ HDL: improvement in HDL remodeling without effects on cholesterol absorption (Q37163072) (← links)
- The hypertension peril: lessons from CETP inhibitors (Q37369256) (← links)
- Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review (Q37494202) (← links)
- Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents (Q37575509) (← links)
- Hepatic transforming growth factor-β 1 stimulated clone-22 D1 controls systemic cholesterol metabolism (Q37636425) (← links)
- Anacetrapib: hope for CETP inhibitors? (Q37734553) (← links)
- Surrogate end points: how well do they represent patient-relevant end points? (Q37755085) (← links)
- Cholesteryl ester transfer protein and its inhibition (Q37765864) (← links)
- Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion. (Q37774393) (← links)
- Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises (Q37827882) (← links)
- Emerging options in the treatment of dyslipidemias: a bright future? (Q37842462) (← links)
- Drug development in the light of translational science: shine or shade? (Q37912523) (← links)
- New Horizons for Cholesterol Ester Transfer Protein Inhibitors (Q37956122) (← links)
- On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors (Q37987207) (← links)
- How can high-throughput screening deliver drugs to treat atherosclerosis? (Q38028514) (← links)
- Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib (Q38051303) (← links)
- A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs (Q38113494) (← links)
- High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm (Q38203096) (← links)
- Antilipidemic Drug Therapy Today and in the Future (Q38296685) (← links)
- Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism (Q38741861) (← links)
- HDL Measures, Particle Heterogeneity, Proposed Nomenclature, and Relation to Atherosclerotic Cardiovascular Events (Q39789841) (← links)
- Projecting future drug expenditures--2008. (Q40131701) (← links)
- Nanotechnology for synthetic high-density lipoproteins (Q41516063) (← links)
- In vivo triglyceride synthesis in subcutaneous adipose tissue of humans correlates with plasma HDL parameters (Q42359779) (← links)
- Torcetrapib impairs endothelial function in hypertension (Q42726849) (← links)
- Biphenyl-Substituted Oxazolidinones as Cholesteryl Ester Transfer Protein Inhibitors: Modifications of the Oxazolidinone Ring Leading to the Discovery of Anacetrapib (Q42732186) (← links)
- Effect of drugs on high-density lipoprotein (Q42752809) (← links)
- Early termination of drug trials (Q42951671) (← links)